University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
NCT Number: NCT06547788
Mitral valve leakage, or mitral regurgitation (MR), is associated with heart failure symptoms including shortness of breath, fatigue, irregular heart rate. When left untreated, it may cause death. Patients with MR can be divided in two broad groups: those with primary MR, caused by disease of the mitral valve structures, and those with secondary MR, due to dilation of the heart chambers. Our study focuses on patients with primary MR.
The standard treatment for severe symptomatic primary MR is mitral valve surgery, a type of open-heart surgery. The outcomes following this procedure are excellent, however, a subset of patients continue to experience heart failure symptoms after surgery due to very high pressures in the heart, more specifically in the left atrium, which is one of the four heart chambers. This is called functional mitral stenosis (FMS).
Previous studies have shown that creating a small opening between the left and right atria can help relieve the pressure inside the left atrium. We would like to determine whether creating this opening between the two atria at the time of mitral valve surgery can help prevent FMS. To answer this question, we will study two groups of patients who need mitral valve surgery for primary MR. The first group will undergo mitral valve surgery, along with the creation of the opening between the two atria. The second group will undergo mitral valve surgery alone. We will then compare the outcomes between both groups, namely with regards to their heart failure symptoms after open-heart surgery.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Ottawa, Ontario, K1Y 4W7, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Mitral valve repair with creation of an 8 mm inter-atrial shunt
Time frame: 30 Months
Process, Resources, Management, Scientific
Time frame: 30 Months
Process, Resources, Management, Scientific
Time frame: 30 Months
Process, Resources, Management, Scientific
Contact information is provided by the study sponsor or research team.
Alice Black
CONTACT
Kenza Rahmouni El Idrissi, Dr.
CONTACT
Ottawa Heart Institute Research Corporation
Other
Acronym: LAMBDA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06667128
Aortic Regurgitation Disease, Aortic Stenosis
Milan, Italy
View Trial DetailsNCT05871983
Cardiovascular Diseases, Heart Diseases
Buenos Aires, Argentina
View Trial DetailsNCT04729933
Cardiovascular Diseases, Heart Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT03339115
Cardiovascular Diseases, Heart Diseases
Bonn, North Rhine-Westphalia, Germany
View Trial Details